Eli Lilly lowers out-of-pocket price of Zepbound weight loss drug
December 2, 2025
Source: drugdu
62
LillyThe company announced that, starting December 1, the self-paid price of Zepbound through the LillyDirect platform will be reduced from the previous $349-$499 per month to $299-$449.
The starting dose has been reduced to $299 per month, the 5mg dose to $399 per month, and all higher doses to a uniform $449 per month. Zepbound's list price is approximately $1086 per month. This price reduction primarily targets the single-dose vial of Zepbound, which requires patients to self-inject, aiming to circumvent high prices and unstable insurance coverage.The barriers to coverage should be addressed to provide more affordable treatment options for out-of-pocket patients.
This price reduction comes after the Trump administration pushed for an agreement to lower the price of GLP-1 drugs, following competition from Novo Nordisk.They have also recently lowered the price of their weight-loss drugs.Out-of-pocket prices for Wegovy and the diabetes medication Ozempic.
https://finance.eastmoney.com/a/202512023579780327.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
